SEC Form 4 · accession 0001479290-19-000002
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Cyril Allouche
Officer — Principal Accounting Officer
Period of report
Dec 31, 2018
Accepted (ET)
Jan 2, 2019 · 8:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 31, 2018 | J | 375 | $17.1105 | A | 4,375 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were acquired by Mr. Allouche under the Issuer's 2014 Employee Stock Purchase Plan (the "Plan") on December 31, 2018 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Mr. Allouche purchased the maximum number of shares allowable under the Plan and Internal Revenue Code Section 423(b)(8) for the period ended December 31, 2018.